Donald Hayden

Insmed Ltd. develops and manufactures pharmaceutical products for the treatment of lung diseases. Its products are used for the site-specific treatment of serious lung diseases such as pulmonary infections in cystic fibrosis patients and cancers affecting the lung. The company is located in London, the United Kingdom.

Vitae Pharmaceuticals LLC is a clinical-stage bio-pharmaceutical company, which engages in discovering and developing novel, small molecule drugs for diseases, including chronic kidney disease, diabetes and Alzheimer's disease, and autoimmune disorders, acute coronary syndrome, and immuno-oncology. The company was founded by John J. Baldwin, Bartosz A. Grzybowski, George M. Whitesides, and Eugene Shakhnovich on May 21, 2001 and is headquartered in Fort Washington, PA.

Satori Pharmaceuticals, Inc. developed therapeutics for alzheimer's disease. The firm's drug candidates selectively modulated gamma secretase, the enzyme generating the neurotoxic peptides that form amyloid beta plaques the signature of this debilitated disease. The company was founded by Mark A. Findeis and Dennis J. Selkoe in 2005 and was headquartered in Cambridge, MA.

Nora Therapeutics, Inc. develops therapeutics to address clinical unmet needs in reproductive medicine. Its's lead product NT100, seeks to improve pregnancy outcomes in women undergoing in vitro fertilization or who have suffered recurrent spontaneous miscarriages. The company was founded by Darryl L. Carter and Chris B. McClain in 2007 and is headquartered in Palo Alto, CA.

Azelon Pharmaceuticals, Inc. develops biopharmaceutical drugs for the treatment of osteoporosis. It develops parathyroid hormone analogs for the treatment of bone diseases, which are characterized by deficits in bone formation, including osteoporosis, orthopedic conditions and renal bone disease. The company was founded by Paul Morley and Godfrey Marchand in 2000 and is headquartered in West Conshohocken, PA.

Otsuka Pharmaceutical Co. Ltd. engages in the manufacturing, distributing, exporting, and importing of pharmaceuticals, clinical testing equipment, medical device and equipment, food products, cosmetics, and other related products. Its operations are carried out through the following business divisions: Pharmaceutical Business and Nutraceutical Business. The Pharmaceutical Business division engages in the manufacture and sale of pharmaceutical products for the diagnosis and treatment of diseases. The Nutraceutical Business division provides nutritional products, cosmetics and medicines that support day-to-day health maintenance and improvement. The company was founded on August 10, 1964 and is headquartered in Tokyo, Japan.

Alvine Pharmaceuticals, Inc. develops and commercializes therapeutics for inflammatory diseases. It offers ALV003, tTG Inihibitors and HLA-DQ2 Blockers. The company was founded by Blair Stewart and Kevin R. Kaster in 2005 and is headquartered in San Carlos, CA.

Dimension Therapeutics, Inc. engages in the development of novel treatments for rare diseases. Its activities include discoveries and development of therapeutic products for people living with rare diseases associated wit the liver and caused by genetic mutations. The company was founded by Ben Auspitz in June 20, 2013 and is headquartered in Cambridge, MA.

Otsuka America Pharmaceutical, Inc. manufactures and supplies pharmaceutical products. It develops drugs for neuroscience, cardiovascular, and gastrointestinal treatments. The company was founded in 1989 and is headquartered in Rockville, MD.

WindMIL Therapeutics, Inc. operates as a biotechnology company. It develops immunotherapies for the treatment of cancer patients. The company was founded by Ivan Borrello and Kimberly Noonan and is headquartered in Baltimore, MD.

Theseus Pharmaceuticals, Inc. engages in the development of pan-variant kinase inhibitors. It focuses on the discovery, development and commercialization of transformative targeted therapies. The company was founded by William C. Shakespeare, David C. Dalgarno, Iain D. Dukes, Wei Sheng Huang and Victor M. Rivera on December 29, 2017 and is headquartered in Cambridge, MA.

Avanir Pharmaceuticals, Inc. engages in the development of therapeutic products for the treatment of nervous system disorder. The company was founded on August 31, 1988 and headquartered in Aliso Viejo, CA.